Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508258 | 0.85 | — | — | |
| SCHEMBL3906654 | 0.82 | CA2 (0.32) | CA2 | |
| SCHEMBL508399 | 0.81 | — | — | |
| SCHEMBL6507208 | 0.78 | TAS2R38 (0.32) | — | |
| SCHEMBL1507929 | 0.77 | CA2 (0.43) | CA2 | |
| SCHEMBL1332813 | 0.75 | — | — | |
| SCHEMBL6983915 | 0.75 | CA2 (0.31) | CA2 | |
| SCHEMBL2286616 | 0.75 | ALDH1A1 (0.30) | — | |
| SCHEMBL28109785 | 0.75 | ALDH1A1 (0.30) | — | |
| SCHEMBL508234 | 0.75 | NOS1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115915795-A | Perovskite solar cell containing double-layer trifluoroacetate modification layer and preparation method thereof | 河北工业大学 | 2023-04-04 | — | — | CN | claimed |
| US-8425702-B2 | Precursor of an explosive composition including at least one ionic liquid and a method of desensitizing an explosive composition | ALLIANT TECHSYSTEMS INC. (US) | 2013-04-23 | — | — | US | claimed |
| US-20120024437-A1 | PRECURSOR OF AN EXPLOSIVE COMPOSITION INCLUDING AT LEAST ONE IONIC LIQUID AND A METHOD OF DESENSITIZING AN EXPLOSIVE COMPOSITION | ALLIANT TECHSYSTEMS INC. (US) | 2012-02-02 | — | — | US | claimed |
| US-8012277-B2 | Mixture with activator; desentization melt | ALLIANT TECHSYSTEMS INC. (US) | 2011-09-06 | — | — | US | claimed |
| US-20080251169-A1 | IONIC LIQUID, A METHOD OF SYNTHESIZING AN IONIC LIQUID, A PRECURSOR OF AN EXPLOSIVE COMPOSITION INCLUDING AT LEAST ONE IONIC LIQUID, AND A METHOD OF DESENSITIZING AN EXPLOSIVE COMPOSITION | ALLIANT TECHSYSTEMS INC. (US) | 2008-10-16 | — | — | US | claimed |
| US-12516892-B2 | Inverted barocaloric effects | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-01-06 | — | — | US | disclosed |
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2025-08-26 | — | — | US | disclosed |
| EP-4602126-A1 | INVERTED BAROCALORIC EFFECTS | President and Fellows of Harvard College (US) | 2025-08-20 | — | — | EP | disclosed |
| WO-2024081374-A9 | INVERTED BAROCALORIC EFFECTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | Aucentra Thereapeutics Pty LTD (AU) | 2025-02-20 | — | — | US | disclosed |
| US-20250012516-A1 | INVERTED BAROCALORIC EFFECTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2025-01-09 | — | — | US | disclosed |
| CN-114269742-B | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amine as therapeutic agents | 常州千红生化制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-1351602-A | Novel Pharmaceutically Active Compounds | ASTRAZENECA AB (SE) | 2002-05-29 | — | — | CN | disclosed |
| EP-0805685-B1 | NOVEL ANTIFUNGAL CYCLOHEXAPEPTIDES | MERCK & CO INC (US) | 2001-09-26 | — | — | EP | disclosed |
| CN-1289326-A | N-[(substituted five-membered di-or thiaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER PROD INC (US) | 2001-03-28 | — | — | CN | disclosed |
| CN-1237961-A | Aminoguanidines and alkoxyguanidines as protease inhibitors | DIMENSIONAL PHARM INC (US) | 1999-12-08 | — | — | CN | disclosed |
| US-5854213-A | Antifungal cyclohexapeptides | MERCK & CO., INC. (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0805685-A4 | NOVEL ANTIFUNGAL CYCLOHEXAPEPTIDES | MERCK & CO INC (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0805685-A1 | NOVEL ANTIFUNGAL CYCLOHEXAPEPTIDES | Merck & Co., Inc. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022784-A1 | NOVEL ANTIFUNGAL CYCLOHEXAPEPTIDES | MERCK & CO., INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | CA2 4750/4885 |
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | FLT3, CDK2, CDK4 | CA2 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.